JP2024514935A5 - - Google Patents
Info
- Publication number
- JP2024514935A5 JP2024514935A5 JP2023564409A JP2023564409A JP2024514935A5 JP 2024514935 A5 JP2024514935 A5 JP 2024514935A5 JP 2023564409 A JP2023564409 A JP 2023564409A JP 2023564409 A JP2023564409 A JP 2023564409A JP 2024514935 A5 JP2024514935 A5 JP 2024514935A5
- Authority
- JP
- Japan
- Prior art keywords
- frα
- composition according
- subject
- less
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/060749 WO2021214329A1 (en) | 2020-04-24 | 2021-04-23 | Composition comprising an ige antibody |
| EPPCT/EP2021/060749 | 2021-04-23 | ||
| GBGB2109550.0A GB202109550D0 (en) | 2021-07-01 | 2021-07-01 | Composition |
| GB2109550.0 | 2021-07-01 | ||
| PCT/EP2022/060693 WO2022223784A1 (en) | 2021-04-23 | 2022-04-22 | Composition comprising an ige antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514935A JP2024514935A (ja) | 2024-04-03 |
| JP2024514935A5 true JP2024514935A5 (cg-RX-API-DMAC7.html) | 2025-04-18 |
Family
ID=81750377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564409A Pending JP2024514935A (ja) | 2021-04-23 | 2022-04-22 | IgE抗体を含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240190955A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326770A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514935A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240001136A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022263376A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021873A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215850A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012557A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022223784A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202309456B (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CN105777907B (zh) | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| ES2654160T3 (es) | 2011-10-04 | 2018-02-12 | Igem Therapeutics Limited | Anticuerpos de IgE anti-HMW-MAA |
| BR112019023909A8 (pt) | 2017-05-16 | 2023-04-11 | Immunogen Inc | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab |
| GB202006093D0 (en) * | 2020-04-24 | 2020-06-10 | King S College London | Composition |
-
2022
- 2022-04-22 AU AU2022263376A patent/AU2022263376A1/en active Pending
- 2022-04-22 US US18/287,623 patent/US20240190955A1/en active Pending
- 2022-04-22 JP JP2023564409A patent/JP2024514935A/ja active Pending
- 2022-04-22 CA CA3215850A patent/CA3215850A1/en active Pending
- 2022-04-22 EP EP22724722.8A patent/EP4326770A1/en active Pending
- 2022-04-22 BR BR112023021873A patent/BR112023021873A2/pt unknown
- 2022-04-22 KR KR1020237035816A patent/KR20240001136A/ko active Pending
- 2022-04-22 WO PCT/EP2022/060693 patent/WO2022223784A1/en not_active Ceased
- 2022-04-22 MX MX2023012557A patent/MX2023012557A/es unknown
-
2023
- 2023-10-10 ZA ZA2023/09456A patent/ZA202309456B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180161293A1 (en) | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate | |
| JP2007515469A5 (cg-RX-API-DMAC7.html) | ||
| JPH03188021A (ja) | レトロウイルスを撲滅するための医薬品およびその製造法 | |
| WO2015090162A1 (zh) | 一种含有阿达木单抗的药物组合物 | |
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2017533274A (ja) | メトトレキサート製剤 | |
| CN103877101A (zh) | 葫芦素在制备抗肿瘤药物中的应用 | |
| US20190241660A1 (en) | Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer | |
| US11974993B2 (en) | Solution formulations of CX-011 | |
| SK129999A3 (en) | Pharmaceutical composition, preparation process and use thereof | |
| US9919053B2 (en) | Cabazitaxel composition | |
| US12533373B2 (en) | β-glucan composition and use therefor | |
| US20250049869A1 (en) | Use of auricularia auricula total polysaccharide or monomeric polysaccharide in preparation of pd-l1 inhibitor | |
| CN120390655A (zh) | 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途 | |
| CN111393278B (zh) | 一种长松萝衍生物及其在制备治疗胆囊癌药物中的用途 | |
| TWI822897B (zh) | 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途 | |
| JPS6310685B2 (cg-RX-API-DMAC7.html) | ||
| CN113082203B (zh) | 一种免疫抑制剂单克隆抗体的液体制剂 | |
| WO2019114125A1 (en) | A novel quinochalcone compound and uses thereof for treating cancer or inflammation | |
| CN119700764B (zh) | 恩波吡维铵在制备抗基孔肯亚病毒感染药物中的应用 | |
| CN104000835A (zh) | P糖蛋白抑制剂 | |
| CN117442590A (zh) | 包含紫檀芪的药物组合物及其制备方法与制药用途 | |
| CN111728960B (zh) | 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用 | |
| JPS6213922B2 (cg-RX-API-DMAC7.html) | ||
| CN111065405A (zh) | 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法 |